A clinical double-blind trial comparing amorolfine cream 0·5% (RO-14-4767) with bifonazole cream 1% in the treatment of dermatomycoses |
| |
Authors: | A DEL PALACIO-HERNANZ S LÓPEZ-GÓMEZ P MORENO-PALANCAR F GONZÁLEZ-LASTRA |
| |
Institution: | Department of Microbiology;Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain |
| |
Abstract: | In a double-blind parallel study, 40 patients with dermatomycoses (one cutaneous candidosis and 39 dermatophyte infections) were treated topically with amorolfine (RO-14-4767) cream (0.5%), a new antifungal compound, or with bifonazole cream (1%). The treatment was applied once daily and was continued until 1 week after resolution of the symptoms, the maximum duration of treatment was limited to 6 weeks. Assessment of results was based on both clinical and mycological parameters. The percentages of amorolfine- and bifonazole-treated patients who were clinically and mycologically cured were 83.33% and 78.95%, respectively. Two patients treated with amorolfine and one patient treated with bifonazole were withdrawn from the trial because of side-effects. There was no significant difference between the two creams in clinical and mycological cure rates and tolerance. |
| |
Keywords: | |
|
|